3
Announcements
Trials
Browse
Landscape
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Observational
1
Sponsor
Cancer Type
Other solid neoplasm
1
Dermatologic
1
Classical hematology
1
CNS
1
Conditions
Urinary Tract Infections
1
Staphylococcal Infections
1
Spasm
1
Sleep Initiation and Maintenance Disorders
1
Sepsis
1
Seizures
1
Schizophrenia, Treatment-Resistant
1
Schizophrenia
1
Retinitis
1
Renal Insufficiency, Chronic
1
Pulmonary Arterial Hypertension
1
Pneumonia
1
Pain
1
Neutropenia
1
Migraine Disorders
1
Menorrhagia
1
Meningitis, Bacterial
1
Meningitis
1
Intraabdominal Infections
1
Influenza, Human
1
Inflammation
1
Infections
1
Hypokalemia
1
Hypertension
1
Hyperaldosteronism
1
Herpes Simplex
1
Hemophilia A
1
Hemangioma, Capillary
1
Heart Failure
1
Heart Arrest
1
Interventions
fludarabine phosphate
58
Cyclophosphamide
54
Epoetin Alfa
43
Cyclosporine
43
Busulfan
43
Peripheral Blood Stem Cell Transplantation
39
Mycophenolic Acid
34
Darbepoetin alfa
33
Antilymphocyte Serum
31
Whole-Body Irradiation
30
Cytarabine
30
Filgrastim
29
Methotrexate
26
Tacrolimus
25
Radiotherapy
25
Melphalan
24
fludarabine
21
Methylprednisolone
17
Cord Blood Stem Cell Transplantation
17
Etoposide
14
Granulocyte Colony-Stimulating Factor
13
Daunorubicin
13
Rivaroxaban
12
apixaban
11
Thiotepa
11
sargramostim
10
epoetin beta
10
Dalteparin
10
eltrombopag
9
Alemtuzumab
9
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Bosentan
×
Classical hematology
×
Clear all
NCT01431326
2023-09-06
PTN_POPS
Duke University
Completed
3,520 enrolled